19/12/2018 – AB Science provides the main achievements of this restructuring. Post navigationPreviousPrevious post:PatientsNextNext post:Acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association ConferenceRelated PostsMasitinib phase 3 study in Alzheimer’s disease has completed patient recruitmentOctober 22, 2018Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral SclerosisOctober 8, 2018First half of 2018 revenuesOctober 1, 2018Positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancerJuly 23, 2018Results of the Combined General Shareholders’ Meeting held on June 29 2018July 3, 2018Combined General Shareholders’ Meeting held on June 29, 2018July 3, 2018
Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral SclerosisOctober 8, 2018
Positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancerJuly 23, 2018